Skip to main content

Stephen Feider

Equibles does not estimate personal net worth.

Get an email with a short summary when Beta Bionics, Inc. publishes a filing, an earnings call transcript or a press release.

Get BBNX alerts

About Stephen Feider

Stephen Feider is recorded as CFO at Beta Bionics, Inc. (BBNX). The newest filing on record that lists Stephen Feider as CFO at Beta Bionics, Inc. (BBNX) is dated April 10, 2026. The proxy statement of Beta Bionics, Inc. reports total compensation of $5,198,180 for Stephen Feider in fiscal 2025, including a base salary of $475,000. Disclosed compensation is on record for 2 fiscal years. Stephen Feider has spoken on 5 earnings calls across 1 company, most recently for Beta Bionics, Inc. on April 21, 2026. Beta Bionics, Inc. is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Beta Bionics, Inc. includes Sean Saint (CEO and Board Member) and Gerard Michel (Board Member).

Stephen Feider on recent calls

“Our Q1 performance exceeded our expectations across the board. Revenue performance was mainly driven by new patient starts and the recurring revenue generated from our growing pharmacy installed base.”
CFO, Beta Bionics, Inc. Q1 FY2026 Earnings Call ·
“Our Q4 revenue, pharmacy mix, and gross margin results surpassed our guidance across the board. Although we don't typically provide guidance on this metric, our 5,592 new patient starts increased by 5% sequentially compared to the previous quarter, aligning with the lower end of our expectations for the quarter.”
CFO, Beta Bionics, Inc. Q4 FY2025 Earnings Call ·
“Approximately 70% of our 5,334 new patient starts in Q3 came from people with diabetes that used multiple daily injections prior to starting the iLet, which is an important representation of how much the iLet is expanding the market for insulin pumps and addressing an unmet need.”
CFO, Beta Bionics, Inc. Q3 FY2025 Earnings Call ·
“Approximately 71% of our 4,934 new patient starts in Q2 came from people with diabetes that use multiple daily injections prior to starting the iLet.”
CFO, Beta Bionics, Inc. Q2 FY2025 Earnings Call ·
“Diving deeper into our Q1 performance, approximately 71% of our 3,853 new patient starts in Q1 came from people with diabetes who use multiple daily injections prior to starting the iLet.”
CFO, Beta Bionics, Inc. Q1 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Beta Bionics, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Beta Bionics, Inc. (BBNX) $475,000 $5,198,180
2024 Beta Bionics, Inc. (BBNX) $358,333 $659,583

Recent activity